Phase II dose-ranging study of veltuzumab in systemic lupus erythematosus.
Phase of Trial: Phase II
Latest Information Update: 15 May 2013
At a glance
- Drugs Veltuzumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Immunomedics
- 15 May 2013 Study title is not official title.
- 15 May 2013 New trial record
- 08 May 2013 A pre-IND meeting request and an application for scientific advice have been filed in the USA and European Union, respectively, according to an Immunomedics media release.